Johnson & Johnson (NYSE: JNJ) offered to acquire breast implant maker Mentor Corp (NYSE: MNT). At $31 per share, J&J's tender offer for Mentor is a 92% premium to its closing price last Friday.

J&J plans to run the $373 million Mentor as a stand-alone business under its Ethicon division, reasoning that the skills of its 1,300 employees will strengthen J&J's presence in aesthetic and reconstructive medicine. Mentor is not just about breast implants -- mostly for cancer patient reconstruction. It is also awaiting FDA approval for face fillers, which would enable Mentor (and now J&J) to compete in the market for wrinkle treatment that Botox now dominates.

The Mentor announcement comes on the heels of a $438 million J&J deal to buy Omrix Biopharmaceuticals Inc. (NASDAQ: OMRI) giving J&J full access to products that control bleeding during surgery. The Mentor purchase is expected to cut J&J's 2009 earnings by 3 to 5 cents a share.

Mentor's stock popped 90% in response to the $1.12 billion takeover deal. This is pretty good for a day when the Dow is plunging over 300.

J&J's decision to make acquisitions in a down market looks pretty shrewd to me as long as these acquisitions eventually add to earnings.

Peter Cohan is President of Peter S. Cohan & Associates. He also teaches management at Babson College and edits The Cohan Letter. He has no financial interest in the securities mentioned.

Breast implant maker stock expands 90% originally appeared on BloggingStocks on Mon, 01 Dec 2008 10:55:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• B. Riley initiated Wilmington Trust (NYSE: WL) with a Neutral rating and $33 target and points out the company has greater exposure to construction and development loans than most small- and mid-cap banks.
  
• DiamondRock Hospitality (NYSE: DRH) was assumed with a Market perform rating and $13.50 target at Keefe Bruyette. The firm sees limited upside given expectations for continued moderation in RevPAR trends, limited operating margin expansion and an uncertain economic outlook.
  
• Rodman & Renshaw believes that the issues that have plagued Omrix Biopharm (NASDAQ: OMRI) are now largely reflected in shares and that the company has improved visibility on business fundamentals with solid execution. The firm assumed coverage with an Outperform rating and $18 target.

• UBS initiated Millennium Pharma (NASDAQ: MLNM) with a Neutral rating and $16 target.
  
• Credit Suisse initiated Ryanair (NASDAQ: RYAAY) with a Neutral rating.
  
• Morgan Stanley started Brasken (NYSE: BAK) with an Underweight rating.

Analyst initiations: WL, DRH and OMRI originally appeared on BloggingStocks on Mon, 31 Mar 2008 11:44:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Stanford finds shares of Alliance Imaging (NYSE: AIQ) fairly valued and believes the company's transition to providing imaging services to hospitals from mobile imaging equipment to fixed imaging equipment will take at least several years. The firm initiated coverage with a Hold rating.
  
• Calpine (NYSE: CPN) was initiated with a Buy rating and $21.50 target at Jefferies. The firm views Calpine as a low-cost valuation generation company and expects earnings growth from its Western and Texas power plants to drive improved results.
  
• Cowen assumed CommVault (NASDAQ: CVLT) with a Neutral rating and sees limited upside to 2009 estimates due to sales and marketing investments, as well as competition.

• UBS initiated Omrix Biopharm (NASDAQ: OMRI) with a Buy rating and $17 target.
  
• Susquehanna initiated Align Tech (NASDAQ: ALGN) with a Neutral rating.
  
• Zions Bancorp (NASDAQ: ZION) was assumed with a Neutral rating and $13 target at Baird.

Analyst initiations: AIQ, CPN and CVLT originally appeared on BloggingStocks on Thu, 27 Mar 2008 12:45:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY:

• Banc of America initiated six stocks in the newspaper sector with Neutral ratings: Gannett (NYSE: GCI) was started with a $51.50 target, citing a lack of clarity into the company's acquisition strategy; New York Times (NYSE: NYT) was started with a $21 target, reflecting a lack of clarity into the company's acquisition strategy; E.W. Scripps (NYSE: SSP) was started with a $43 target, as the firm feels the company's Interactive division is a "big question mark" that could drag down company growth; McClatchy Co (NYSE: MNI) was started with a $26 target, as the firm is positive longer-term, but sees downside risk to 2007 consensus estimates; Lee Enterprises (NYSE: LEE) was initiated with a $19.50 target; Gatehouse Media (NYSE: GHS) was started with a $12.50 target.
  
• Dolan Media (NYSE: DM) was initiated with an Outperform rating and $24 target at Piper Jaffray. Piper believes DM's Q3 guidance is conservative given the default rates in July and August and notes the company processes defaults in two of the three highest default rate states. Dolan Media was also started with a Buy rating and $26 target at Merrill Lynch and with a Buy rating and $28 target at Craig-Hallum.

• Think Equity assumed coverage of Intel Corporation (NASDAQ: INTC) and Micron Technology (NYSE: MU) with an Accumulate rating and $26 target and a Buy rating and $18 target, respectively.
• Citigroup started shares of Royal Caribbean Cruises (NYSE: RCL) and Carnival Corp (NYSE: CCL) with Hold ratings.
• SuperValu Inc (NYSE: SVU) was started with a Hold rating and $47 target at Citigroup.
• Rodman & Renshaw initiated shares of Omrix Biopharmaceuticals (NYSE: OMRI) with a Market Outperform rating.

Analyst initiations 9-11-07: Select newspaper stocks and DM originally appeared on BloggingStocks on Tue, 11 Sep 2007 10:55:00 EST. Please see our terms for use of feeds.